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ABSTRACT 
 
The present study was carried out to investigate the toxic effects of 
Monosodium glutamate (MSG) on Wistar albino rats. 
Twenty rats were divided into four groups, five rats each, one group was 
left as control and the other groups were treated with three different levels 
of MSG (120, 240, 480 mg/kg body weight). 
Clinical symptoms throughout the experimental period which lasted for 28 
days were recorded. 
Body weights, relative organs weight, some serum constituents and 
haematological changes beside histopathology of liver and brain were 
measured. 
Higher levels of MSG showed paralysis in one leg, dizziness, hyperactivity 
and disorientation which reflected disturbances in the Central Nervous 
System.  
The results indicated that MSG had no significant effects on body weight 
and relative weight of livers and kidneys, and haematological values. 
Higher levels of MSG resulted in significant increase in activity of 
transeaminase enzymes and significant decrease in total protein 
concentration. 
Histopathological examination of the liver showed degeneration and 
vaculation of hepatocytes beside dilation of sinosoids, while brain tissue 
showed congestion, oedema around the neurons, vaculation and neuronal 
necrosis. 
This results prove that MSG has a toxic effects on liver and brain tissues. 
The toxicity increase whenever the rate of the salt increased too. 
This study recommends that the necessity of avoiding the use of MSG as 
additive compress to human and animals` food because o f toxic effects of 
this salt. 
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  اﻷﻃﺮوﺣﺔﺧـﻼﺻـﺔ 
 
أﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻟﻔﺤﺺ اﻟﺘﺄﺛﻴﺮات اﻟﺴﻤﻴﺔ ﻟﻤﻠﺢ ﻗﻠﻮﺗﺎﻣﻴﺖ اﻟﺼﻮدﻳﻮم اﻷﺣﺎدى ﻋﻠﻰ 
  .اﻟﻔﺌﺮان
  . ﻓﺄرًا اﻟﻰ أرﺑﻌﺔ ﻣﺠﻤﻮﻋﺎت، ﺧﻤﺴﺔ ﻓﺌﺮان ﺑﻜﻞ ﻣﺠﻤﻮﻋﺔ02ﻢ ﺗﻢ ﺗﻘﺴﻴ
أﺳﺘﺨـﺪﻣﺖ ﻓﻰ هـﺬﻩ اﻟﺪراﺳﺔ ﺛﻼﺛﺔ ﻣﺴﺘﻮﻳﺎت ﻣﻦ ﻣﻠﺢ ﻗﻠﻮﺗﺎﻣﻴﺖ اﻟﺼﻮدﻳﻮم اﻷﺣﺎدى 
 .(آﺠﻢ ﻣﻦ وزن اﻟﺠﺴﻢ/ ﻣﻠﺞ084، 042، 021)
ﺗﻢ ﻗﻴﺎس وزن اﻟﺠﺴﻢ واﻟﻮزن اﻟﻨﺴﺒﻰ ﻟﻠﻜﺒﺪ واﻟﻜﻠﻰ، ﺑﻌﺾ ﻣﻜﻮﻧﺎت اﻟﺴﻴﺮم، اﻟﺘﻐﻴﺮات ﻓﻰ 
ﺄﺛﻴﺮ اﻟﻤﺮﺿﻰ ﻋﻠﻰ أﻧﺴﺠﺔ اﻟﻜﺒﺪ واﻟﻤﺦ ﺑﺎﻻﺿﺎﻓﺔ اﻟﻰ ﻣﻼﺣﻈﺔ ﻣﻜﻮﻧﺎت اﻟﺪم واﻟﺘ
  . ﻳﻮﻣًﺎ82اﻻﻋﺮاض اﻻآﻠﻴﻨﻴﻜﻴﺔ ﺧﻼل ﻓﺘﺮة اﻟﺘﺠﺮﺑﺔ واﻟﺘﻰ إﺳﺘﻤﺮت 
زﻳﺎدة ﻧﺴﺒﺔ ﻣﻠﺢ ﻗﻠﻮﺗﺎﻣﻴﺖ اﻟﺼﻮدﻳﻮم اﻷﺣﺎدى أدت اﻟﻰ ﻇﻬﻮر أﻋﺮاض إآﻠﻴﻨﻴﻜﻴﺔ ﻣﺜﻞ 
ﻌﻜﺲ ذﻟﻚ ﺷﻠﻞ إﺣﺪى اﻷرﺟﻞ، دوار، ﻧﺸﺎط زاﺋﺪ و ﻋﺪم اﻟﻤﻘﺪرة ﻋﻠﻰ ﺗﺤﺪﻳﺪ اﻻﺗﺠﺎﻩ وﻳ
  .وﺟﻮد إﺿﻄﺮاﺑﺎت ﻓﻰ اﻟﺠﻬﺎز اﻟﻌﺼﺒﻰ اﻟﻤﺮآﺰى
أﺛﺒﺘﺖ اﻟﻨﺘﺎﺋﺞ أن ﻣﻠﺢ ﻗﻠﻮﺗﺎﻣﻴﺖ اﻟﺼﻮدﻳﻮم اﻷﺣﺎدى ﻟﻴﺲ ﻟﻪ ﺗﺄﺛﻴﺮ ﻣﻌﻨﻮى ﻋﻠﻰ وزن 
اﻟﺠﺴﻢ واﻟﻮزن اﻟﻨﺴﺒﻰ ﻟﻠﻜﺒﺪ واﻟﻜﻠﻰ، آﺬﻟﻚ ﻟﻢ ﻳﻼﺣﻆ أى ﺗﺄﺛﻴﺮ ﻣﻌﻨﻮى ﻋﻠﻰ ﻣﻜﻮﻧﺎت 
  .اﻟﺪم
ﻮى ﻋﻠﻰ زﻳﺎدة ﻧﺸﺎط إﻧﺰﻳﻤﻰ زﻳﺎدة ﻧﺴﺒﺔ ﻣﻠﺢ ﻗﻠﻮﺗﺎﻣﻴﺖ اﻟﺼﻮدﻳﻮم اﻷﺣﺎدى ﻟﻬﺎ ﺗﺄﺛﻴﺮ ﻣﻌﻨ
  .اﻟﻘﻠﻮﺗﺎﻣﻴﺖ ﺗﺮاﻧﺴﺎﻣﻴﻨﺎز وإﻧﺨﻔﺎض اﻟﺘﺮآﻴﺰ اﻟﻜﻠﻰ ﻟﻠﺒﺮوﺗﻴﻦ ﺑﺎﻟﺴﻴﺮم
أﻇﻬﺮت ﻧﺘﺎﺋﺞ ﻓﺤﺺ اﻻﻧﺴﺠﺔ ﻟﻘﻄﺎﻋﺎت اﻟﻜﺒﺪ ﺗﻨﻜﺲ اﻟﺨﻼﻳﺎ اﻟﻜﺒﺪﻳﺔ و ﺗﻔﺠﻰ وﺗﻮﺳﻊ 
أﻇﻬﺮت ﻗﻄﺎﻋﺎت اﻟﻤﺦ إﺣﺘﻘﺎن ووذﻣﺔ ﺣﻮل اﻟﻌﺼﺒﻮﻧﺎت وﺗﻔﺠﻰ وﻧﺨﺮ ﺑﻴﻨﻤﺎ   اﻟﺠﻴﺒﺎﻧﻴﺎت
  .اﻟﻌﺼﺒﻮن
xi 
ﺜﺒﺖ أن ﻣﻠﺢ ﻗﻠﻮﺗﺎﻣﻴﺖ اﻟﺼﻮدﻳﻮم اﻷﺣﺎدي ﻟﻪ أﺛﺎر ﺳﺎﻣﻪ ﻋﻠﻲ أﻧﺴﺠﺔ اﻟﻜﺒﺪ هﺬﻩ اﻟﻨﺘﺎﺋﺞ ﺗ
  . وﺗﺰداد اﻟﺴﻤﻴﺔ ﻣﻊ زﻳﺎدة ﻧﺴﺒﺔ اﻟﻤﻠﺢواﻟﻤﺦ
ﺗﻮﺻﻲ هﺬﻩ اﻟﺪراﺳﺔ ﺑﻀﺮورة ﺗﺠﻨﺐ اﺳﺘﺨﺪام ﻣﻠﺢ ﻗﻠﻮﺗﺎﻣﻴﺖ اﻟﺼﻮدﻳﻮم اﻷﺣﺎدي آﻤﺎدة 
  . ﻣﻀﺎﻓﺔ ﻟﻐﺬاء اﻹﻧﺴﺎن واﻟﺤﻴﻮان ﻟﻶﺛﺎر اﻟﺴﺎﻣﺔ ﻟﻬﺬا اﻟﻤﻠﺢ
 
 
 x
INTRODUCTION  
 
Food additives used to enhance the taste of food or to alter the taste so as to 
mask disagreeable taste and magnify desired one. 
They all have nothing to do with preserving food or protecting its integrity.  
Monosodium glutamate (MSG), a food additive, is the sodium salt of the 
non-essential amino acid glutamic acid. Glutamic acid is one of the most 
abundant amino acids found in nature and exists both as free glutamate and 
bound with other amino acids into protein.  
Glutamate is thus found in a wide variety of foods, and in its free form, 
where it has been shown to have a flavour enhancing effect. 
As a result of its flavour enhancing effect, glutamate is often deliberately 
added to foods either as purified monosodium salt (MSG) or as a 
component of a mixture of amino acids and small peptides resulting from 
the acidic or enzymatic hydrolysis of proteins. 
MSG has been implicated as the causative agent in the symptom complex 
known as Chinese restaurant syndrome 
The purpose of this study is to determine if MSG has the potential to cause 
severe adverse reactions and excitotoxic effects on Wister albino rats.  
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Chapter One 
Literature Review 
 
1.1. Physical and Chemical Properties of MSG 
 
 
 
 
 
Fig [1]:- The Chemical Structure of Monosodium Glutamate 
 
Monosodium glutamate (C5H8NNaO4), European Union (EU) food additive 
code E621 commonly known as MSG is a sodium salt of glutamic acid. It 
is popularly marketed as flavor enhancer. In its pure form, it appears as a 
white crystalline powder, when dissolved in water or saliva it rapidly 
dissociates into sodium cations and glutamate anions (www.wikipedia.org). 
The chemical structure of MSG is shown in figure [1] above. 
MSG has no texture or smell of its own (Singh, 2005). 
MSG is readily soluble in water but sparingly soluble in ethanol. MSG is 
not hygroscopic and is considered quite stable, it does not change in 
appearance or quality during prolonged storage at room temperature. MSG 
does not decompose during normal food processing or cooking but in 
acidic conditions (pH 2.2-2.4) and at high temperatures it is partially 
dehydrated and converted to 5-pyrrolidone-2-carboxylate (Yamaguchi and 
Ninomiya, 1998).  
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An anionic form of MSG at physiological pH known as glutamate. 
Glutamate is one of many different amino acids, which are considered to be 
the building blocks of protein. Glutamate itself is regarded as one of the 
most important components in proteins (Michele et al, 1999).  
More specifically, MSG is a manufactured glutamate to which a sodium 
ion has been attached. It is comprised of nothing more than water, sodium 
and glutamate (www.wikipedia.org). 
1.2. Uses of MSG 
The use of MSG in food began in the early 1900s as a component of flavor 
enhancer. 
MSG is used to enhance the natural flavors of meat, poultry, seafood, 
snacks, soups and stews (Institute of Food Technologists, 1987a). 
Food palatability increases with appropriate concentrations of MSG 
(Halpern, 2000). 
The amount of glutamate used in foods is usually within the range of 0.1% 
to 0.8% of the food. This is similar to levels of naturally occurring 
glutamate found in traditional dishes. This mean that once the appropriate 
amount has been included in a recipe, adding more contribute little to 
flavor or may even be detrimental to the flavor balance of the dish 
(FAO/WHO, 19701). 
MSG basically causes the nerve cells to discharge an electrical impulse and 
that’s the basis of its use as a flavor enhancer. It could also suppress or off 
undesirable flavors, bitterness and sourness and eliminated the tinny taste 
of canned food (Schwartz, 1988). 
1.3. Sources of Glutamate 
1.3.1. Natural Sources 
Glutamate occurs naturally in every plant and animal as a part of enzymes 
and structural proteins. Free glutamate is also found in varying amounts in 
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many foods. Most proteins found in plants and animals contain from 5-25 
% glutamate (Raiten et al, 1995). 
Glutamate is found in abundance in both free and bound forms in all 
natural food stuffs; meat, poultry, fish, cheese, milk including human 
breast milk, tomatoes, mushrooms and many other vegetables 
(www.msg.org).  
Of the twenty free amino acid in human breast milk, glutamate is the most 
abundant, accounting for >50% of the total free amino acid content (Rassin 
et al, 1978).  
The free form of glutamate not linked to protein, in food increase its 
content during natural ripening of fruits (www.msg.org). 
1. 3. 2. Commercial Sources 
Although an extract of seaweed has been used by oriental cultures to 
enhance food flavor for over 1,000 years, it was not until 1910 that the 
essential component responsible for the flavor phenomenon was identified 
as glutamate and industrial production of glutamate and MSG commenced 
(Kizer et al, 1978).   
From 1910 until 1956, the process underlying production of glutamate was 
one of extraction, a slow and costly method.  In 1956, the Japanese 
succeeded in producing glutamate by means of fermentation; thus large-
scale production of glutamate began (Nostrand, 1983). 
MSG is created when protein is either partially or fully broken apart into its 
constituent amino acids, or glutamic acid is secreted from selected bacteria. 
A protein can be broken into its constituent amino acids in a number of 
ways (autolysis, hydrolysis, enzymolysis, and/or fermentation).  In general, 
these processes are referred to as hydrolyzation of protein. When a protein 
is hydrolyzed, the amino acid chains in the protein are broken, and 
individual amino acids are freed. Acids, enzymes, and/or fermentation 
processes are used to hydrolyze protein (Leung and Foster, 1996). 
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The fermentation process was invented by Kyowa Hakko Kogyo in 1957.  
A nonpathogenic species of Coryneform bacterium Corynebacterium 
glutamicum was originally isolated as an L-glutamate producing bacteria 
and is now used for industrial fermentative production of various amino 
acids (Takashi et al, 2001).  
Mutation in it’s A gene causes a growth defect and induce L-glutamate 
overproduction by C-glutamicum. [Figure 2] (Pamela and Richard, 1994).  
Other organisms identified to produce L-glutamate are Brevibacterium, 
Arithrobacter and Microbacterium. (John and Bjorn, 1987). 
The fermentation process begins with natural products such as molasses 
from sugar cane or sugar beets and food starch from tapioca or cereals with 
fermented in a controlled environment with a microorganism. 
The crude glutamate produced in this process is then filtered, purified and 
converted by neutralization into MSG.  After additional purification, 
crystallization, drying and sieving, MSG has the form of pure white 
crystals ready for packing and use (www.msg.org). 
Combining specific amino acids, reducing sugars, animal or vegetable fats 
or oils, can also produce MSG (Lin, 1993). 
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                      Glucose  
 
       Phosphoenol pyruvate                                Pyruvate   
 
                               Co2                                                     Co2 
       Pyrophenol                                                           Pyruvate 
Pyruvate                                                      dehydrogenase   
     Carboxylase 
  
                  Oxaloacetate                                   Acetyl CoA 
 
 
 
             Malate                                         Citrate 
 
 
                                             Ketoglutarate 
                                            Dehydrogenase 
               Succinyl CoA                              ά-keto glutarate 
                                   Co2                                          Glutamate                           
  dehydrogenase 
                                            
                                           L-glutamate 
 
 
Fig [2]: - L-glutamate Production Pathway Reactions with 
                         C. Glutamicum Organism. 
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1.4. Flavoring Enhancement Properties of MSG 
Flavors probably exert their effect by increasing the number of molecules 
that interact with receptors on chemosensory membranes in the nose and 
oral cavity and compensate for chemosensory losses. This intensification of 
chemosensory stimulation induces more salivation, produces greater 
stimulation of the olfactory and limbic system of the brain. Amplification 
of flavor and taste with MSG can improve food palatability and 
acceptance. MSG adds an additional taste but does not enhance any other 
tastes (Schiffman, 2000).  
The use of MSG in food goes back to the oriental cooks who used seaweed 
called sea tangle to make a stock that added richness to the flavor of foods 
cooked in it. Professor Kikunae Ikeda discovered the link between the 
seaweed flavor improvement and glutamate in 1908. He demonstrated that 
the seaweed Laminaria japonica contained generous amounts of glutamate 
and that’s the seaweed component responsible for food flavor enhancement 
(Institute of Food Technologests, 1980). 
Glutamate is the key component in determining the flavor of protein-
containing foods (FDA Backgrounder, 1995). 
There are two types of glutamate; L- and D-isomers. L-glutamate is a 
natural component of protein, but D-glutamate is not. Flavoring action is 
recognized only in L-glutamate, and not in D- glutamate (Kuninaka et al, 
1964). 
When present in its free form, not bound together with other amino acids in 
protein, glutamate has a flavor enhancing effect in foods. When MSG is 
added to foods, it provides a flavoring function similar to the naturally 
occurring free glutamate (Institute of Food Technologists, 1987). 
Only the free forms of glutamate have an effect on the glutamate receptors 
but when bound to other amino acids in a protein, it does not stimulate 
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glutamate receptors (Löliger, 2000).  
MSG brings out the best natural flavors in food, working well in reduced-
sodium and reduced-fat dishes and can reduce total sodium by 30-40 
percent without influencing palatability (Yamaguchi and Takahashi, 1984). 
Fuke and Shimizu (1993) indicated that MSG falls outside the region 
occupied by the four classic tastes of sweet, sour, salty and bitter. 
This distinctive taste is known as umami, a word coined by the Japanese to 
describe the taste imparted by glutamate. Westerners often describe this 
flavor as savory, broth-like or meaty (Yamaguchi, 1987).  
The tongue is sensitive to five flavors, salt, sweet, bitter, sour, and umami 
(Schiffman, 2000).  
The substances which constitute the umami taste can be divided in two 
main groups: one is the amino acid group, represented by monosodium 
glutamate and the other is the 5'-nucleotid group, represented by inosine 5'-
monophosphate (IMP) and guanosine mono phosphate (GMP) and their 
derivatives (Papi, 2003).  
MSG, with or without 5'-ribonucleotides, likely exerts its effect by adding 
another taste quality to the food which improves palatability (Bellisle et al, 
1991).  
Neither MSG nor 5'-ribonucleotides appear to exert their effect by altering 
the perceived intensity of other components of food or altered the 
intensities of salts, sweeteners, amino acids or bitter compounds 
(Schiffman, 2000).  
The basic sensory function of MSG is attributed to its ability to enhance the 
presence of other taste-active compounds. Foods containing MSG have a 
typical salty taste, because it contains 12.3 % sodium. The detection 
threshold for MSG is 6.25 × 10 -4 mol/L, which interestingly is higher than 
 8
for bitterness or sourness, and lower than that for sweetness and about 
equal to that for saltiness. In general, the usage level of MSG in savory 
foods is approximately one tenth that of salt; thus the sodium contribution 
of MSG is roughly one thirtieth of the total added sodium. By adding MSG 
appropriately, the sodium chloride addition could be reduced by 30-40 % 
while maintaining the same perception of saltiness. Results of taste panel 
studies on processed foods indicate that an MSG level of 0.2-0.8 % of food 
by weight optimally enhances the natural food flavor (Löliger, 2000).  
Bellisle et al. (1996) stated that addition of MSG to nutritionally valuable 
foods would represent a mean to selective develop preference for food or to 
enhance its intake without increasing total energy intake. 
The optimal palatability concentration for MSG is between 0.2-0.8% and 
its use tends to be self-limiting as over-use decrease palatability. The 
largest palatable dose for humans is about 60mg/kg body weight (Walker 
and Lupien, 2000) 
1.5. Metabolism and Synthesis of Glutamate 
Glutamate performs essential roles in intermediary metabolism and present 
in large amounts in the organs and tissues of the body. The daily turn over 
of glutamate in the adult human has been estimated as 4800m/h (Munro, 
1979). 
Human brain is the only tissue that has the highest content of glutamate 
(Hardman et al, 2001). 
The majority of the glutamate used by the brain is derived from local 
synthesis from glutamine and tricarboxylic acid cycle (TCA) intermediates 
and a considerable fraction is also derived from the recycling of brain 
protein (Smith, 2000).  
As part of protein digestion, protein is broken down into its constituent’s 
amino acids. The ingested protein is hydrolyzed in the stomach and lower 
intestine through the action of hydrochloric acid and enzymes. In the 
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human body, glutamate can be formed from ingested protein (Freedland 
and Briggs., 1977). 
The body controls the amount of glutamate converted from protein in this 
way and dispose of the waste, human do not store glutamate as such 
(Burgess, 1988). 
Glutamate plays a central role in transamination reaction in which amino 
acids funnel their amino group to α-ketoglutarate resulting in glutamate 
formation. Glutamate therefore acts as an acceptor of amino group from 
other amino acids and further undergoes either oxidative deamination in 
liver or is used as amino group donor in synthesis on non-essential amino 
acids. Glutamate thus undergoes either transamination, resulting in 
formation of α-ketoglutarate, which enters TCA cycle and aspartate which 
enters urea cycle or oxidative deamination in the liver by the enzyme 
glutamate dehydrogenase resulting in the liberation of free ammonia which 
enters urea cycle (Chanda et al, 2005). 
Glutamate is absorbed from the gut by an active transport system specific 
for amino acids (Schultz et al, 1970). 
During intestinal absorption, a large proportion of glutamate is 
transaminated and consequently alanine levels in portal blood are elevated. 
If large amounts of glutamate are ingested, portal glutamate levels increase 
(Stegink, 1984). This elevation results in increased hepatic metabolism of 
glutamate, leading to release of glucose, lactate, glutamine and other amino 
acids into systemic circulation (Stegink, 1983). 
Glutamic acid in dietary protein, together with endogenous protein secreted 
into the gut, is digested to free amino acids and small peptides, both of 
which are absorbed into mucosal cells where peptides are hydrolyzed to 
free amino acids and some of glutamate is metabolized. Excess glutamate 
appears in the portal blood where it is metabolized by the liver. As a 
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consequence of the rapid metabolism of glutamate in intestinal mucosal 
cells, with any excess glutamate being metabolized by the liver, systemic 
plasma levels are typically low, even after ingestion of large amounts of 
dietary protein (Munro, 1979). 
A number of early studies with dogs (Neame and Wiseman, 1958), and 
later, studies conducted in rats (Windmueller, 1982), demonstrated that the 
vast majority of dietary glutamate is metabolized by the gastrointestinal 
tract. In fact, very little dietary glutamate enters either the systemic or the 
portal blood supply. Young and Ajami et al. (2000) indicated that 
glutamate is almost exclusively utilized by the intestinal tissues.  
Moreovere, Olney (1975) stated that there is differences between ingesting 
a free amino acid, and ingesting of amino acid bound in protein, in the 
former case, absorption of the entire amino acid load is immediate and this 
leads to much higher peaking of the amino acid level in the blood than if a 
similar amount were released slowly by over a matter of hours by the 
digestive process. There is evidence that the gut transaminate glutamate to 
alanine, an amino acid that does not have excitotoxic potential and this may 
represent a protective mechanism to prevent elevated blood levels of this 
neurotoxic amino acid. 
Hence, bound glutamate found naturally in foods, is less dangerous, and 
can be utilized by the tissues before toxic concentrations can be built 
(Blaylock, 1998).  
However, composition of the dosing vehicle as well as the conditions of 
administration of the dose has significant impact on changes in circulating 
glutamate in response to oral ingestion (Raiten et al, 1995). 
The process of dietary glutamate utilization by the intestinal tract has 
recently been extensively studied. The results showed that 95% of dietary 
glutamate presented to the mucosa was metabolized in first pass and that of 
this, 50% appeared as portal CO2, with lesser amounts as lactate and 
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alanine. This indicates that glutamate is the single largest contributor to 
intestinal energy generation. The studies also indicated that about 10% of 
dietary glutamate is incorporated into mucosal protein synthesis, with the 
remainder being used for the synthesis of proline, arginine and glutathione. 
In fact, all three substances proline, arginine and glutathione are derived 
almost exclusively from dietary glutamate, rather than the vast in vivo pool 
of glutamate (Reeds et al, 2000). 
Glutamate transportors in skeletal muscles and heart appear to play a role 
in the control of the steady-state concentration of amino acids in the 
intracellular space probably through osmatic signaling mechanisms to 
regulate whole body protein metabolism (Rennie et al, 1996). 
The fate of ingested MSG in some cases does not come to rest in the 
plasma as elevated plasma glutamate and from there to be excreted by the 
liver. Rather it would appear that the fate of ingested processed free 
Glutamic acid might be dispatch to any glutamate receptors available and 
create adverse or toxic reactions if the peripheral glutamate receptors are 
weak, crippled, diseased or otherwise unhealthy (www.truthinlabeling.org). 
1. 6.  Adverse Reactions to MSG 
In 1968, a letter was published in the New England Journal of Medicine 
describing a syndrome, which began 15 to 30 minutes after eating Chinese 
food containing MSG, and lasted about 2 hours with no lasting effects. The 
symptoms were described as numbness at the back of the neck gradually 
radiating to both arms and the back, general weakness and palpitation 
(Kwok, 1968). 
Schaumburg et al. (1969) reported results of studies they had under taken. 
This times both headache and chest pains were added to the symptoms list. 
Later on, there have been reports of tachycardia (Gann, 1977), hyperactive 
or hysterical activity in children (Asnes, 1980), paraesthesiae of hands and 
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feet (Freed and Carter, 1982), severe burning headache, severe upper 
abdominal pain, pressure accompanied by diaphoresis and a burning 
sensation in the chest (Ratner et al, 1984), angio-oedema (Squire, 1987) 
and a hypertensive reaction in the form of vascular headache (Pohl et al, 
1988). 
Studies completed in the 1970s in United States declared that at least 25 
percent of the population reacts to MSG in processed food (Reif-Lehrer, 
1977). 
Reif-Lehrer and Stemmermann (1975) stated that children react to 
ingestion of MSG and describing CNS symptoms similar to adults with 
almost the same degree of prevalence. She discussed the fact that glutamic 
acid has been reported to cause convulsive disorders in animals. 
Subsequently, Andermann commented on a possible relationship between 
glutamic acid and essential tremor (Andermann et al, 1975).  
Colman (1978) stated two cases of psychiatric reactions to monosodium 
glutamate.  
Ratner et al. (1984) stated that the initial diagnoses in seven patients, 
whose complaints were eventually resolved as MSG sensitivity, were 
migraine, myocardial infarction, brain tumor, neurosis, functional colitis, 
and depression.  
Schwartz (1988) reported that MSG-reactions range from mild and 
transitory to debilitating and/or life threatening, including skin rash, simple 
headache, nausea/vomiting, asthma-like symptoms, migraine headache, 
tachycardia, panic attack, anaphylactic shock, seizures and depression. 
In 1995, the Federation of American Societies for Experimental Biology 
(FASEB), who had been commissioned by the United States Food and 
Drug Administration (FDA) to undertake a review of reported adverse 
reactions to MSG, reported that the following symptoms are considered 
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representative of the acute, temporary, and self-limited reactions to oral 
ingestion of MSG (FASEB, 1995):  
- Burning sensations in the back of the neck, forearms, and chest.  
- Facial pressure/tightness. 
- Chest pain. 
- Headache. 
- Nausea. 
- Palpitation. 
- Numbness in back of neck, radiating to arms and back.  
- Tingling, warmth, weakness in face, temples, upper back, neck and arms 
- Drowsiness. 
- Weakness.  
In some recently conducted studies, the most frequently reported symptoms 
were headache, numbness/tingling, flushing, muscle tightness, and 
generalised weakness (Yang et al, 1997 and Geha et al, 2000).  
Ingestion of processed free glutamic acid causes adverse reactions in 
susceptible individuals. The fairly recent discovery of glutamate receptors 
in many locations outside the central nervous system suggests that the 
readily observable toxic effects of processed free glutamic acid, referred to 
as adverse reactions, are facilitated by glutamate receptors in the mouth, 
lungs, intestines, and muscle (Gill et al, 2000). 
Symptoms are reported to occur at doses like 1.5 and 12g of glutamate 
after 15-25 minutes. The threshold range for intravenous dose is 25-125 mg 
for minimum symptoms to occur after 17-20 seconds. At supra-threshold 
dose, tightness, pressure over malar, numbness, burning sensation over 
chest, forearms, abdomen, and thighs have been reported 
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(www.truthinlabeling.org). 
Onset time for the adverse reactions being considered as possible reactions 
to MSG was 10-25 minutes with duration of 45 minutes to 2 hours. 
1.7. MSG Excitotoxicity 
There is increasing scientific evidence, however, that taste cells on the 
tongue are not only the things that taste enhancers stimulate. When neurons 
in the brain are exposed to these substances, they become very excited and 
fire their impulses rapidly until they reach a state of extreme exhaustion. 
Several hours later these neurons suddenly die, as if the cells were excited 
to death (Shambaugh, 1996). 
The toxicity of glutamate was observed in 1957 when the feeding of MSG 
to newborn mice destroyed the neurons in the inner layers of the retina 
(Lucas and Newhouse, 1957). 
Olney (1969) discovered that the phenomenon wasn't restricted to the 
retina but occurred throughout the brain and coined the term excitotoxicity. 
Excitotoxicity is the pathological process by which neurons are damaged 
and killed by over activations of receptors for glutamate (Manev et al, 
1989). 
Glutamate is required for normal brain function while excess amount leads 
to neuronal death due to the destructive effect mediated by glutamate 
receptors (Shaw, 1999). 
Excitotoxicity can occur from substances produced within the body. 
Glutamate is a prime example of an excitotoxin in the brain, and it is 
paradoxically also the major excitatory neurotransmitter in the mammalian 
central nervous system (CNS) (Temple et al, 2001). 
Glutamate ability to destroy neurons is mediated by the interaction with N-
methyl-D-aspartate (NMDA) receptors which induces intracellular calcium 
increase, free radical generation, and activation of proteases, 
phospholipases and endonucleases, and the transcriptional activity of 
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apoptotic programmers (Pelligrini et al, 1997). 
During normal conditions, glutamate concentration can be increased up to 
1mM in the synaptic cleft, which is rapidly decreased in the lapse of 
milliseconds. When glutamate concentration around the synaptic cleft 
cannot be decreased or reaches higher levels, the neuron kills itself by   
apoptosis process (Kanded et al, 2000). 
At chemical synapses, glutamate is stored in vesicles. Nerve impulses 
trigger release of glutamate from the pre-synaptic cells. In the opposing 
post-synaptic cells, glutamate receptors bind glutamate and activated 
(www.wikipedia.org). 
Shigeri et al. (2004) stated that glutamate transporters are found in 
neuronal and glial membranes. They rapidly remove glutamate from the 
extracellular space. In brain injury or disease, they can work in reverse and 
excess glutamate can accumulate outside cells. 
Normally excess glutamate bumped back in the glial cells surrounding the 
neurons. However, when cells are exposed to excessive amount of 
glutamate, the neuron cells die. Glutamate opens the calcium channel in the 
neuron so that calcium can move into the cell. Magnesium normally blocks 
the calcium channel from opening. Glutamate removes this block and 
opens the calcium channel, a normal reaction. However, when glutamate 
levels become even slightly excessive, the calcium channel in some neural 
cells can get stuck open, leading to destruction of those cells and adjacent 
cells. Not every nearby brain cell is affected, only the cells with glutamate 
receptors (www.holistimed.com). 
Sometimes the cells are damaged without being killed because of the 
particular functions of the brain areas where these cells are located. The 
mode of action of excitotoxins on an individual neuron has been shown to 
weaken the membrane that surrounds each living cell. While exciting the 
neurons to fire repeatedly, the excitotoxins allows calcium to enter the cell 
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through its membrane. This causes the production of free oxygen radicals, 
which are believed to be the central cause for every injury and disease 
(Blaylock, 1994). 
Glutamate is used as a neurotransmitter by glutamate-type neurons. 
Surrounding these neurons are helper cells, called asrtocytes, which 
regulate the concentration of glutamate by absorbing any excess and 
converting it into glutamine. If the asrtocytes are deprived of glucose or 
oxygen they become energy depleted and spill glutamate, killing or 
damaging these neurons in the absence of any excess dietary glutamate. 
When excess glutamate is present, it is one hundred times more toxic if the 
brain is also deprived of glucose. Since glutamate occurs naturally in foods, 
the brain has a second mechanism to help prevent excessive glutamate 
levels, the blood-brain barrier, which has an increased capability to 
transport beneficial substances such as glucose and exclude detrimental 
ones such as glutamate (Blayloch, 1994). 
Excitotoxins play a critical role in the development of several neurological 
disorders including migraines, seizures, infections, abnormal neural 
development, certain endocrine disorders, neuropsychiatric disorders, 
learning disorders in children, episodic violence, hepatic encephalopathy, 
specific types of obesity, and especially the neurodegenerative diseases 
such as amyotrophic lateral sclerosis (ALS), parkinson's disease and 
alzheimer's disease (Ikonomidou and Turski, 1995). 
1. 8.  MSG and Central Nervous System 
Research over the course of the last four decades has demonstrated that in 
addition to its role as a building block of protein, glutamic acid serve as a 
neurotransmitter vital to the transmission of nerve impulses in many parts 
of the (CNS) (Shank and Aprison, 1988). 
Glutamate is the major excitatory transmitter within the brain, mediating 
fast synaptic transmission and is active in perhaps one third of (CNS) 
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synapses (Watkins and Evans, 1981).   
It has also been demonstrated that under certain circumstances, glutamic 
acid, along with other acidic amino acids, functions as a neurotoxin, 
causing neuron degeneration and neuroendocrine disorders in a variety of 
laboratory animals (Garattini, 1979). 
Glutamate is widely available in (CNS). It is highly concentrated in those 
regions of the brain that are essential in cognitive processes mediation, eg. 
cerebral cortex, hippocampus gyrus dentatus and striatum, indicating an 
important role of this amino acid in higher cognitive functions including 
memory (Cotman et al, 1987). 
Cellular bodies of hypothalamic secretory neurons are situated in the areas 
protected by the blood-brain barrier, while their terminal axons are 
localized in eminentia mediana which lacks blood-brain barrier (Peruzzo et 
al, 2000). That is the reason why the eminentia mediana region which 
accepts the axonal terminals from the nearby arcuate nucleus and other 
hypothalamic secretory neurons is most sensitive to glutamate exposure. 
Moreover, the fenestrated capillary endothelium of the eminentia mediana 
makes it available to plasma amino acids; so that the initial glutamate 
induced neuronal damage could be the result of circulating level of these 
acids rather than the cerebro-ventricular pool. The arcuate nucleus-
eminentia mediana region in the early postnatal period in rodents was an 
often used as a model in the studies of MSG induced neurotoxcicity due to 
its marked sensitivity, consistent cytoarchitecture and prominent anatomic 
site (Takasaki, 1978).   
Though the tanycyte modified astroglial cells forming tight connections 
and making up the inner blood-brain barrier surface network is already 
established in neonatal mice, arcuate and other neuronal axons is grown 
into eminentia mediana during the first 25 days of neonatal life (Eurenius 
and Jarskar, 1971). 
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Large doses of MSG administrated to immature animals do not cause 
evident tanycyte or eminentia mediana terminal axons damage, but the 
arcuate nucleus neurons are significantly damaged (Holzwarth-McBride et 
a, 1976).  
This nucleus is the production site of numerous stimulatory and inhibitory 
hormones, that is why the disturbance of its function in neonatal period by 
MSG treatment leads to numerous endocrine and metabolic disorders and 
altered behaviour in the adult age (Klingberg et al, 1987 and Olney, 1969). 
Neurotoxic effects of MSG induce growth retardation, obesity and sterility, 
reduction of growth hormone, gonadal steroid and thyroid hormone levels 
(Bake et al, 1978). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Two 
Materials and Methods 
 
2. 1. Materials and Experimental Design 
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2. 1. 1. Monosodium Glutamate 
Monosodium glutamate in a white granular crystalline form was brought 
from Omdurman Central Market. Sudan. 
2. 1. 2. Animals 
Twenty healthy Wistar albino rats of both sexes were supplied by breeding 
unit at Central Veterinary Research Laboratory. Soba. 
They were housed under standard conditions and have free access to water 
and standard diet. 
They were left for two weeks as an adaptation period. 
2. 1. 3. Experimental Design 
At the end of the adaptation period the rats were divided randomly into 
four groups, five rats each. Group A was left as a control, while group B, C 
and D were orally administrated with MSG using gastric tube daily at 
concentrations of 120, 240 and 480 mg/kg body weight respectively for 28 
days. 
2. 1. 4. Parameters 
Clinical signs and mortality were recorded. Blood samples were obtained 
for haematological investigation included red blood cells (RBCs) count, 
white blood cells (WBCs) count, packed cell volume (PCV) and 
haemoglobin (Hb) concentration. 
Serum investigation included total protein concentration (TP), alanine 
amino transferase (ALT) activity, aspartate amino transferase (AST) 
activity and alkaline phosphatase (ALP) activity. 
Slices from liver and brain were collected and fixed in 10% neutral 
buffered formalin for histopathological investigation. 
2. 2. Methods 
2. 2. 1. Haematological Methods 
Blood samples were collected by puncturing the rat's retro orbital plexus 
with heparinized capillary tube (SUPE-PIRO-GERMAN code N-4361) into 
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dry clean tube containing ethylene diamine tetra acetic acid (EDTA) as an 
anticoagulant according to Waynforth (1980). 
2. 2. 1. 1. Red Blood Cells (RBCs) Count 
 RBCs were counted using improved Neubaur haemocytometer (Hawksly 
and son Ltd, England). Haymem`s solution was used as diluent (Sodium 
Chloride 1.0g, Sodium Sulphate 0.5g, Mercuric Chloride 0.5g and made up 
to 200ml with distilled water. RBCs were expressed in million/mm3 blood. 
2. 2. 1. 2. White Blood Cells (WBCs) Count 
WBCs were counted using improved haemocytometer (Hawksly and son 
Ltd, England). Turk's solution was used as diluent. WBCs were expressed 
in thaousand/mm3 blood. 
2. 2. 1. 3. Packed Cell Volume (PCV) 
PCV was measured using haematocrit method. Blood samples were placed 
in the capillary haematocrit tube and centrifuged using haematocrit 
centrifuge (Hawksly and son Ltd, England). 
The PCV percent was read off on the scaling instrument provided with 
microhaematocrit. 
2. 2. 1. 4. Haemoglobin (Hb) Concentration 
The determination of Hb concentration was based on the conversion of Hb 
to cyanomethaemoglbin by means of Drabkin's solution (Potassium 
cyanide 0.5g, Potassium ferricyanide 0.2g and Potassiun hydrogen orthro 
phosphate 0.14g in liter distilled water). The colored solution was read with 
spectrophotometer (JENWAY 6305 UV/VIS) at wave length 540 nm and 
compared against standard Hb (cromatest). 
Haemoglobin concentration was expressed as follow: 
Hb (g/dl) = Tested Sample × 15 
               Standard 
 
 
Where 15 was standard concentration. 
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2. 2. 2. Serum Biochemical Methods 
Blood samples were collected in a similar procedure as for haematology 
into dry clean tubes without anticoagulant and allowed to clot at room 
temperature for 30 minutes then centrifuged (Hittich EBA35) at 3000 r. p. 
m for 5 minutes. Sera were separated and stored at -20 C˚ till analyses. 
 2. 2. 2. 1. Total Protein (TP) Concentration 
The determination of TP concentration was done according to Biuret 
method (Reinhold, 1953). 
The principal of this method is based on the reaction of peptide bond with 
cupric ion in alkaline media, the Biuret solution (Sodium potassium 
tartarate 9.0g in 500ml 0.2N sodium hydroxide, cupric sulphae 3.0g, 
potassium iodine 5.0g and made volume to one liter with 0.2N sodium 
hydroxide). This result in formation of colored complex. 
The colored solution was read with spectrophotometer (JENWAY 6305 
UV/VIS) at a wave length of 540nm. 
The total protein concentration was calculated as follow: 
 
TP (g/dl) = Tested Sample × 6 
                     Standard Protein 
 
Where 6 was standard concentration. 
2. 2. 2. 2. Transaminase Enzymes 
The transaminase enzymes, aspartate transaminase (AST) and alanine 
transaminase (ALT) catalyze the transfer of the amino group of glutamic 
acid to oxaloacetic acid and pyruvic acid in reversible reactions. 
The transaminases activity is proportional to the amount of oxaloacetate or 
pyruvate formed over a definite period of time and is measured by a 
reaction with 2,4-dinnitrophenyl hydrazine (DNPH) in alkaline solution. 
The determination of transaminases activity was done according to 
colorimetric method (Reitman and Frankel, 1957). 
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2. 2. 2. 2. 1. Alanine transaminase (ALT) Activity 
0.5 ml ALT substrate (Alanine 200mmol/l, Ketoglutarate 2mmol/l) was 
incubated for five minutes at 37˚C, 100µl of sera were added, mixed and 
incubated for 30 minutes, then 0.5ml 2,4-dinitrophenyl hydrazine (DNPH) 
1mmol/l were added, mixed and allow to stand for 20 minutes at room 
temperature. An auxiliary reagent (NaOHO24N 5.0ml) were then added, 
mixed and let to stand for 15minutes at room temperature. 
The optical density was read at 505nm against water blank. 
ALT values were expressed in U/L. 
2.2.2.2.2. Aspartate transaminase (AST) Activity 
Similar procedures as in ALT were carried out except that the solution after 
the addition of serum was incubated for 60 minutes. 
AST values were expressed in U/L. 
2. 2. 2. 3. Alkaline Phosphatase (ALP) Activity 
It is an optimized method according to the recommendation of Chemie 
(1972). 
In alkaline medium serum alkaline phosphatase splits p-nitro-phenyl 
phosphatase, in the presence of Mg+2, into p-nitrophenol and phosphate at 
the pH of the reaction, p-nitrophenyl was coloured yellow, and the optical 
density measured in a spectrophotometer (Jenway 6305 UV/VIS) at a wave 
length of 405 nm. 
p-nitrophenyl phosphatase + H2o → phosphate + p-nitrophenol 
U/I = 2760 × A 405 nm/min. 
(A = the mean of sample absorbance reading) 
2. 2. 2. 4. Histopathological Methods 
Slices from brain and kidney were collected and fixed in 10% neutral 
buffered formalin (Sodium hydrogen 6.5 g/l and Sodium dihydrogen 
4.0g/l), then embedded in paraffin wax sectioned at 5µm and stained by 
Hematoxyline and Eosin (H&E) according to Culling (1974). 
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2. 2. 2. 5.  Statistical Analysis 
Data were analyzed statistically by Statistical Package for Social Scientists 
(SPSS) program, v.13 (2002).  
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Chapter Three 
The Results 
3. 1. Clinical Signs and Mortality 
There were no clinical signs observed in control group. However all groups 
treated with MSG showed signs of shiver, dizziness and disorintation at 
day 14 post treatment. At day 17 there were hyperactivity and hysterical 
signs. 
In group (B) which received 120mg/kg Bwt two rats showed paralysis of 
one leg at day 19 [fig3]. By day 26 paralysis of one leg appeared in most of 
the rats in group (C) and group (D) which received 240 and 480 mg/kg Bwt 
respectively. 
        
Fig [3]: Paralysis in one leg in rat received 480 mg/kg body weight. 
 
3. 2. Body Weight and Relative Organs Weight 
There were no significant differences observed in body weights between 
control rats and treated ones [fig 4]. However the rate of weight gain in 
control rats was 26.4% compared to the group treated with 120mg/kg Bwt 
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which was 30.6%. In group treated with 240 and 480mg/kg Bwt the rate of 
gain was 31.5% and 32.1% respectively. 
There were no significant differences observed in relative weights of liver 
and kidney between control rats and those treated with MSG [fig 5].  
 
 
Fig [4]: The means body weight (mg) in rats treated with  
      various levels of MSG.                         
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Fig [5]: The relative organs weight (mg) in rats treated with  
             various levels of MSG. 
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3. 3. The Haematological Findings 
There were no significant differences in total white blood cell count 
between the control and treated groups [fig 6]. The total red blood cell 
count was high in the groups treated with 480 mg/kg Bwt than the control 
but is not significant [fig 7]. 
The haemoglobin concentration was always similar between the control 
and treated groups [fig 8]. 
The packed cell volume was not significantly different between the control 
and treated groups [fig 9]. 
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Fig [6]: Changes in total white blood cells count in rats treated  
              with various levels of MSG. 
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Fig [7]: Changes in total red blood cells count in rats treated 
              with various levels of MSG. 
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Fig [8]: Changes in haemoglobin concentration in rats treated  
             with various levels of MSG. 
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Fig [9]: Changes in packed cells volume values in rats treated 
              with various levels of MSG. 
 
3. 4 Changes in serum constituents 
The ALT activity was increased significantly in all groups treated with 
MSG [fig 10]. 
There were significant differences in AST activity between the control and 
the treated groups. However, AST was increased significantly between the 
control group and the treated ones [fig 11]. 
The ALP activity increased significantly between the control and the 
treated groups [fig 12]. 
There were significant decreases in total protein concentrations between 
the control group and the treated groups [Fig 13]. 
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Fig [10]: Changes in ALT activity in rats treated with various  
              levels of MSG. 
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Fig [11]: Changes in AST activity in rats treated with various 
              levels of MSG. 
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Fig [12]: Changes in ALP activity in rats treated with various 
                levels of MSG. 
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Fig [13]: Changes in total protein concentration in rats treated 
                with various levels of MSG. 
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3. 5 Histopathological Finding  
In group (B) which treated with 120 mg/kg Bwt the brain showed 
vaculization and infiltration of gilial cells [fig14]. The liver showed 
congestion of central veins and hydropic degeneration of hepatocytes 
characterized by microvesiles inside the cytoplasm [fig 15]. 
In group (C) which treated with 240 mg/kg Bwt the brain showed 
vaculization with congestion of blood vessels and pycnotic neucli [fig 16]. 
There was congestion of central vein and sinasoides with pycnotic neucli 
and small microvacules in cytoplasm in the liver within the same group [fig 
17]. 
In group (D) which treated with 480 mg/kg Bwt the brain was congested 
and showing heamorrhage and infiltration of inflammatory cells in the 
meninges [fig 18]. Congestion of central veins and portal areas were seen 
in liver [fig 19]. 
 
 
 
Fig [14]: Brain section from rat received 120 mg/kg body weight notice 
vaculization and infiltration of gilial cells. (H & E × 40) 
 32
 
 
Fig [15]: Liver section from rat received 120 mg/kg body weight notice 
congestion of central veins and hydropic degeneration of hepatocytes 
characterized by microvesiles inside the cytoplasm. (H & E × 40) 
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Fig [16]: Brain section from rat received 240 mg/kg body weight notice 
vaculization with congestion of blood vessels and pycnotic neucli. (H & 
E × 40) 
 
 
Fig [17]: Liver section from rat received 240 mg/kg body weight notice 
congestion of central vein and sinasoides with pycnotic neucli and 
small microvacules in cytoplasm. (H & E ×40) 
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Fig [18]: Brain section from rat received 480 mg/kg body weight notice 
congestion, heamorrhage and infiltration of inflammatory cells in the 
meninges. (H & E ×40) 
 
  
Fig [19]: Liver section from rat received 240 mg/kg body weight notice 
Congestion of central veins and portal areas. (H & E × 10) 
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Chapter Four 
Discussion 
 
In this study, the groups treated with MSG exhibited clinical symptoms of 
shiver, dizziness, disorientation, hyperactive with hysterical sings and 
paralysis of one leg. The severity of symptoms increased with increased 
levels of MSG. 
These results were similar to those reported by Bhagavan et al. (1971) 
which include somnolence and seizures. Tail automutilation reported by 
Iwata et al. (1979). 
Similar results were reported by Mohd et al. (2000) who claimed that 
administration of MSG to neonatal rats cause neuronal necrosis of the 
hypothalamus along with behavioral abnormalities. 
Learned taste aversion reported by Vogel and Nathan (1975) and irritability 
to touch was interpreted as conspicuous emotional changes by Nemeroff et 
al. (1977). 
MSG is also known to produce a variety of adverse reactions in some 
people which include depression, mood swings, rage reactions, migraine 
headache, dizziness, light-headedness, loss of balance, disorientation, 
mental confusion, anxiety, panic attacks, hyperactivity, behavioral 
problems in children, attention deficit disorders, lethargy, numbness or 
paralysis seizures, shills and shakes, and shuddering 
(www.truthinlabeling.org). 
There were no significant effect on body weight and relative organs weight 
in the present work in rats treated with MSG. This indicates that MSG has 
no effect on the growth rate. This is correlated to Hara et al. (1962) who 
reported that natural and synthetic monosodium L-glutamate at different 
doses when given orally to rats once a day for 90 days had no effects on 
body-weight and relative organs weight.  
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Schoelch et al. (2002) reported that the postweaning development of MSG 
obesity and depressed thermogenesis are preceded by an early phase of 
increased energy expenditure with decreased fat deposition during suckling 
age and hypothesize cell damage in the arcuate nucleus to be involved in 
both. 
In the present investigation MSG levels have no significant effect on 
heamatological values and this agreed with the finding of Geha et al. 
(2000) who confirmed that under controlled conditions no objective 
changes in blood values, except for a transient rise in glutamate levels. 
The reduction of total protein in the treated groups in this study may be due 
to liver damage as illustrated histologically since the liver cells are 
responsible for protein synthesis. The increase in AST, ALT and ALP 
activities is an indication of hepatic damage. These are illustrated by 
pathological changes of the liver. This is in agreement with Cohen (1967) 
who reported that acute irreversible degeneration in liver and retina of 
neonatal mice has been seen following parenteral administration of MSG. 
Diniz et al, (2004) stated that the hepatic glucose metabolic shifting 
induced by hypercaloric diet intake and MSG administration were 
associated with oxidative stress in hepatic tissue.  
The lesions found in the brain in the present work are indications of brain 
toxicity. These findings are similar to findings of Olney (1969) who 
reported that MSG treatment caused brain lesions, particularly acute 
neuronal necrosis in several regions of the developing brain of neonatal 
mice, and acute lesions in the brains of adult mice given 5 to 7 mg/g of 
MSG subcutaneously. Lemkey-Johnston and Reynolds (1974) also 
confirmed that MSG induces neurotoxicity. 
Pardrige (1979) illustrated that dietary glutamate does not enter the brain 
because the blood-brain barrier maintains the transport system for the 
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acidic amino acids, such as glutamate, to effectively exclude circulatory 
glutamate from the brain. 
Several areas in the brain are normally do not have a barrier system, the 
circumventricular areas, these include the hypothalamus, the subfornical 
organ, organium vasculosum, area postrema, pineal gland, and the 
subcommisural organ. 
As stated in literature, glutamate is the most important neurotransmitter in 
the hypothalamus (Shank and Aprison, 1988), Therefore careful regulation 
of blood levels of glutamate is very important, since high blood 
concentrations of glutamate would be expected to increase hypothalamic 
levels as well. 
Exposure to MSG caused damage to arcuate of the hypothalamus as 
indicated by Olney et al, (1977). Takasaki (1979) stated that MSG induces 
hypothalamic damage when given to immature animals after either 
subcutaneous or oral doses. 
Chronic elevations of blood glutamate can even seep through the normal 
blood-brain barrier when these high concentrations are maintained over a 
long period of time (Toth and Lajtha, 1981). 
Coyle et al, (1981) indicated that the damage by monosodium glutamate 
was much more widespread, including the hippocampus, circumventricular 
areas, locus cereulus, amygdala- limbic system, subthalamus, and striatum.  
Sasaki et al, (1994) reported similar results of cell damage in the arcuate 
nucleus. This is one of the most distinct neurotoxic effects of early 
postnatal MSG application, and occurs within a few days. 
Moreover, the blood brain barrier is easily damaged by fever, stroke, and 
trauma to the head, seizures, ingestion of processed free glutamic acid, and 
the normal process of aging (Blaylock, 1994).  
Free glutamic acid including processed free glutamic acid can cross the 
blood brain barrier in an unregulated manner during development, and can 
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pass through the five circumventricular areas, which are leaky at best at 
any stage of life (Skultaetyovaa et al, 1998). 
Park et al, (2000) found that single intraperitoneal injection of 4.0 mg/g 
bodyweight of MSG caused significant damage to hypothalamic neurons in 
the arcuate nucleus and impaired memory retention in adult mice. 
Gonzalez-Burgos et al, (2001) found that subcutaneous administration of 
4.0 mg/g bodyweight of MSG to male neonate rats induced excitotoxicity, 
leading to cell death in prefrontal cerebral cortex. 
Martinez-Contreras et al, (2002) reported administration of 4.0 mg/g body 
weight of MSG caused reactivity of astrocytes and glial cells in the 
frontoparietal cortex, including hyperplasia and hypertrophy. 
In 1968, the first of the observable adverse human reactions to glutamate 
following ingestion of glutamate in food form were noted (Kowk, 1968). 
Since that time, the list of observable adverse reactions has been growing. 
To date little or no research has focused on the mechanisms which cause 
the observable adverse reactions to glutamate; although Zorumski (1990) 
has suggested that research focusing on exogenous food excitotoxins serves 
as a promising source of information for brain research. 
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Conclusions and Recommendations 
 
From the results obtained, we can conclude that: 
(1) MSG cause clinical symptoms which may be related to lesions in the 
brain and the liver. 
(2) MSG has no effect on the rate of growth. 
Further studies can be done on the effect of MSG for longer period of time. 
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